On November 19, 2015 Moffitt Cancer Center and Ignyta, Inc. (NASDAQ: RXDX) reported that they have entered into a research collaboration relating to RXDX-106, Ignyta’s small molecule, pseudo-irreversible inhibitor of TYRO3, AXL, Mer (TAM) and cMET that is in late stage preclinical development (Press release, Ignyta, NOV 19, 2015, View Source [SID:1234508295]).\ Schedule your 30 min Free 1stOncology Demo! The collaboration, which will be conducted in the labs of Eric B. Haura, M.D., director of the Lung Cancer Center of Excellence and leader of the Chemical Biology and Molecular Medicine Program at Moffitt, will explore and develop novel protein based diagnostic assays that can assess RXDX-106 signaling activity in relevant solid tumors and associated tumor microenvironments.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This exciting collaborative partnership with Ignyta will lead to a better understanding of the potential mechanisms of action of RXDX-106 by employing our expertise in cancer proteomic technology," said Haura.
"We continue to work diligently to progress RXDX-106 and the other product candidates we acquired from Teva earlier this year," said Robert Wild, Ph.D., Ignyta’s Chief Scientific Officer and Senior Vice President, Research. "Ignyta’s vision is to be a guiding biotechnology company in precision medicine. We are pleased to be able to collaborate with a world class investigator such as Dr. Haura and his team on the exciting biology relating to RXDX-106."